Abstract Background The mitogen-activated protein kinase (MAPK) signaling pathway is frequently hyperactivated in malignant melanoma and its inhibition has proved to be an efficient treatment option for cases harboring BRAFV600 mutations (BRAFMut). However. there is still a significant need for effective targeted therapies for patients with other melanoma subgroups characterized by co... https://www.spidertattooz.com/